Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents by 菊地, 秀与 et al.
Am J Cancer Res 2019;9(8):1517-1535
www.ajcr.us /ISSN:2156-6976/ajcr0097981
Review Article
Chemopreventive and anticancer activity of flavonoids 
and its possibility for clinical use by combining with  
conventional chemotherapeutic agents
Hidetomo Kikuchi1, Bo Yuan2, Xiaomei Hu3, Mari Okazaki2
1Laboratory of Pharmacotherapy, Department of Clinical Dietetics and Human Nutrition, 2Laboratory of 
Pharmacology, School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 
Keyakidai, Sakado, Saitama 350-0295, Japan; 3Xiyuan Hospital, China Academy of Chinese Medical Sciences, 
Beijing 100091, People’s Republic of China
Received June 4, 2019; Accepted June 11, 2019; Epub August 1, 2019; Published August 15, 2019
Abstract: Cancer is a diverse class of diseases characterized by uncontrolled cell growth with the potential to in-
vade and spread to other parts of the body, and continues to be one of the leading causes of death worldwide. 
Conventional cancer treatment modalities include antitumor drugs, surgical resection, locally targeted therapies 
such as radiation therapy. Along with improved understanding of the molecular pathogenesis of various cancers, 
generation and the use of smart targeted anti-cancer drugs have been challenged. The need for novel therapeutic 
strategies remains paramount given the sustained development of drug resistance, tumor recurrence, and metas-
tasis. Development of new strategies aimed at improving chemotherapy sensitivity and minimizing the adverse side 
effects is thus essential for obtaining satisfied therapeutic outcomes for patients and enhancing their quality of life. 
Emerging evidence has reported that many cancer patients use either herbs employed in complementary therapies 
or dietary agents that influence cellular signaling worldwide. Numerous components of edible plants, collectively 
termed phytochemicals that have beneficial effects for health, are being reported increasingly in the scientific litera-
ture. Of those, flavonoids have attracted much attention by virtue of its wide variety of biological functions includ-
ing antioxidant, anti-inflammatory, and anticancer activity. In this review, we highlight the molecular mechanisms 
underlying its multiple pharmacological effects, especially focusing on cancer chemoprevention. We further discuss 
possible strategies to develop anticancer therapy by combining flavonoids nutraceuticals and conventional che-
motherapeutic agents. We also highlight numerous pharmacokinetic challenges such as bioavailability, drug-drug 
interactions, which are still fundamental questions concerning its future clinical application. 
Keywords: Cancer prevention, flavonoids, anticancer activity, combination treatment, immunosuppression, drug 
transporters, bioavailability, drug-drug interactions
Introduction
Cancer is a diverse class of diseases character-
ized by uncontrolled cell growth with the poten-
tial to invade and spread to other parts of the 
body, and continues to be one of the leading 
causes of death worldwide [1-3]. Previous 
reports have shown differences in cancer mor-
bidity distribution between the developing and 
the developed world, and demonstrated that 
approximately 90-95% of all cancers are attrib-
uted to lifestyle factors, such as smoking, alco-
hol consumption, obesity, diet, physical inac- 
tivity, among other things, while the remain- 
ing 5-10% are due to inherited genes [2, 4]. 
Conventional cancer treatment modalities in- 
clude antitumor drugs, surgical resection, local-
ly targeted therapies such as radiation, radio-
frequency ablation, and photodynamic therapy 
[1, 2, 4]. In addition, along with notable advanc-
es in the understanding of the molecular patho-
genesis of various cancers, generation and the 
use of smart targeted anti-cancer drugs have 
been challenged. For instance, tamoxifen (No- 
lvadex®) and trastuzumab (Herceptin®) have 
already been successfully applied to patients 
diagnosed with estrogen receptor (ER)-positive 
and human epidermal growth factor receptor-2 
(HER2)-positive breast cancer, respectively 
[5]. Furthermore, arsenic trioxide has been 
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approved in the USA and Europe under the 
brand name of Trisenox for ‘the induction of 
remission and consolidation in patients with 
acute promyelocytic leukemia (APL) whose con-
ditions are refractory to, or who have relapsed 
from retinoid and anthracycline chemotherapy, 
and whose APL is characterized by the pres-
[9, 10]. According to the diversity in the struc-
ture, they are further categorized mainly into 
anthocyanins, flavones, flavonols, flavanones, 
flavanonols, flavanols, isoflavones and chal-
cones (Figure 1) [9-11]. Flavonoids exist either 
as glycoside derivatives or as free aglycones to 
form an integral part of the human diet as they 
Figure 1. Basic backbone structure of flavonoids and flavonoid subclasses.
ence of the t(15;17) translo- 
cation or promyelocytic leuke-
mia protein (PML)-retinoic 
acid receptor-α (RARα) fusion 
gene expression’ [6]. Despite 
advances in early detection, 
diagnosis, and targeted treat-
ment options over the past 
two decades, the treatment 
modalities of cancer are still 
insufficient. 
The development of new strat-
egies aimed at improving che-
motherapy sensitivity and mi- 
nimizing the adverse side 
effects is essential for obtain-
ing satisfied therapeutic out-
comes for cancer patients and 
enhancing their quality of life. 
Emerging evidence has report-
ed that many cancer patients 
use either herbs employed in 
complementary therapies or 
dietary agents that influence 
cellular signaling worldwide, 
especially in the areas of Asia 
[6-9]. Numerous components 
of edible plants, collectively 
termed phytochemicals that 
have beneficial effects for he- 
alth, are being reported in- 
creasingly in the scientific lit-
erature [1-3, 9]. These food-
derived phytochemicals and 
their derivatives therefore rep-
resent a cornucopia of new 
anticancer compounds. Of th- 
ose, flavonoids are phenolic 
phytochemicals with a wide 
range of structures consisting 
of two benzene rings designat-
ed as A and B, which are linked 
by three carbons and one oxy-
gen atom to form the central 
pyrone ring, designated as C 
(C6-C3-C6 skeleton; Figure 1) 
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are naturally present in fruits, vegetables, 
grain, tea and wines [9, 10, 12]. Flavonoids 
have attracted much attention by virtue of its 
wide variety of biological functions including 
antioxidant, anti-inflammatory, antibacterial, 
anti-angiogenic, anti-allergic and enzyme mod-
ulation [9-12]. Findings from the epidemiologi-
cal studies suggest that higher dietary intake of 
flavonoids may be inversely associated with 
risk of mortality [7, 13, 14]. Many studies have 
also reported the remarkable and significant 
properties of flavonoids as anticancer and/or 
chemopreventive agents, suggesting a positive 
correlation between a lower risk of cancer and 
a flavonoid-rich diet [1, 9, 10, 15, 16]. Besides, 
it has been recently shown that flavonoids can 
affect immune system response and might 
have immune-modulator effects [8, 16-18]. 
We have been being interested in the effects of 
naturally derived substances including flavo-
noids on different kinds of cancerous cells, 
including human colon carcinoma, breast can-
cer, glioblastoma and leukemic cells [6, 19-32]. 
The promising anticancer activity of phyto-
chemicals thus encourages us to focus on the 
development of novel anticancer therapy by 
combining flavonoids nutraceuticals and con-
ventional chemotherapeutic agents. The aim of 
the present review is to review the progress of 
recent research and available data on the 
molecular mechanisms underlying the multiple 
pharmacological effects of flavonoids, espe-
cially focusing on cancer chemoprevention. We 
further discuss possible strategies to develop 
anticancer therapy by combining flavonoids 
nutraceuticals and conventional chemothera-
peutic agents. We also highlight numerous 
pharmacokinetic challenges such as bioavail-
ability, drug-drug interactions, which are still 
fundamental questions concerning its future 
clinical application. 
Cancer preventive activities of the flavonoids
Contribution of apoptosis, necrosis, cell cycle 
arrest as well as autophagy to cancer preven-
tive activities of flavonoids
Apoptosis is an essential part of the mainte-
nance of tissue homeostasis, and is a tightly 
regulated process under the control of several 
signaling pathways [1, 33]. Generally, apoptosis 
induction occurs through multiple pathways, 
and thus various stimuli activate different path-
ways [1, 6, 33]. So far, two principal signal path-
ways of apoptosis have been identified. The 
intrinsic mechanism of apoptosis involves a 
mitochondrial pathway. Apoptosis stimuli de- 
struct mitochondrial membrane structure un- 
der the control of Bcl-2 (B-cell leukemia/lym-
phoma) family, resulting in the release of mito-
chondrial proteins including cytochrome c. 
Once cytochrome c is released it activates cas-
pase-9 through interaction with Apaf-1 and 
dATP, and ultimately leads to caspase-3 and -7 
activation [1, 6, 33]. On the other hand, the 
extrinsic pathway induced by death receptors, 
such as tumor necrosis factor receptor (TNFR) 
and Fas, which is responsible for the activation 
of caspase-8 and -10 accompanied by the acti-
vation of caspase-3 and -7 [1, 6, 33]. Caspase-3 
and -7 are the final mediators in the two princi-
pal signal pathways that cleave substrates and 
lead to cell death.
Many diseases have been associated with 
aberrantly regulated apoptotic cell death, ulti-
mately leads to inhibition of apoptosis and 
propagation of diseases such as cancer. Most 
of the anticancer therapies trigger apoptosis 
induction and related cell death networks to 
eliminate malignant cells [1, 33]. On the other 
hand, cancer cells are often found to overex-
press many of the proteins that play important 
roles in resisting the activation of apoptotic 
cascade, ultimately escape from apoptosis and 
lead to tumor development, progression and 
treatment resistance [33]. Bcl-2, a well-known 
antiapoptotic factor, functions through hetero-
dimerization with proapoptotic members of the 
BH3 family to prevent mitochondrial pore for-
mation and prevent cytochrome c release and 
initiation of apoptosis [34]. In addition, Bcl-2 
has been suggested to play an oncogenic role 
through survival pathways other than its func-
tions at the mitochondrial membrane [34]. 
Previous reports have shown that overexpres-
sion of Bcl-2 increases the activity of Akt and 
inhibitor of nuclear factor kappa B (NF-κB) 
kinase as well as NF-κB transcriptional activity 
in cancer [33]. Moreover, knock-down of Bcl-2 
by antisense oligodeoxynucleotides induces 
downregulation of carbonic anhydrase IX (CA9) 
(an important pH regulator for the cancer cell 
microenvironment acidification), vascular endo-
thelial growth factor (VEGF), and phosphoryla-
tion of Akt as well as radiation sensitization in 
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prostate cancer cell lines in vitro and in vivo 
[35]. These studies provide evidence in support 
for a multi-functional role of Bcl-2 in cancer 
cells resistant to a variety of chemotherapeutic 
agents. Flavonoids have been reported to tip 
the cellular balance in favor of apoptosis induc-
tion by modulating Bcl-2 and its prosurvival rel-
atives. For instance, casticin, a flavonoid iso-
lated from Vitex species and widely used as an 
anti-inflammatory agent in Chinese traditional 
medicine, dose-dependently induced apopto-
sis along with the activation of intrinsic path-
way accompanied by downregulation of Bcl-2, 
Bcl-xL, survivin, and upregulation of Bax in mul-
tiple cancer cells including esophageal cancer, 
gallbladder cancer, glioblastoma, colon cancer 
and leukemia [24, 36-39]. Similarly, vitexin, a 
naturally-derived flavonoid compound found in 
the traditional Chinese herb Crataegus pinnati-
fida, reduced the Bcl-2/Bax ratio and caused 
the release of cytochrome c from mitochondria 
to cytosol, which further led to the cleavage of 
caspase-3 in human non-small cell lung cancer 
A549 cells [40]. Quercetin, one of the most 
abundant flavonoids present in variety of vege-
tables such as onions and broccoli, has also 
been demonstrate to inhibit the growth of 
human metastatic ovarian cancer cell PA-1 
cells by downregulating the expression of anti-
apoptotic molecules such as Bcl-2, Bcl-xL, and 
upregulating the expression of proapoptotic 
molecules such as caspase-3, caspase-9, Bid, 
Bad, Bax and cytochrome c [41]. Recently, 
Verma et al. reported that polyphenolic com-
pounds including apigenin, fisetin, galangin and 
luteolin bind to the hydrophobic groove of Bcl-2, 
and suggested that these polyphenols have the 
potential to be used as lead molecules for Bcl-2 
inhibition [42]. Moreover, kaempferol, a natural 
dietary flavonoid, suppressed 17β-estradiol- 
induced Bcl-2 and survivin expression and 
caused apoptotic cell death in endometrial can-
cer [43]. 
Intriguingly, the potency of flavonoids to exhibit 
cytotoxicity against cancer cells seems to 
depend on the presence of hydroxyl groups in 
the B-ring, which helps to counteract the pres-
ence/effect of the 3-hydroxyl group [10, 16, 
44]. In agreement with these previous findings, 
we have recently reported that anthocyanidins, 
known as one of the flavonoids with a positive 
charge at the oxygen atom of the C-ring of basic 
flavonoid structure, show cytocidal effects 
against HL-60 cells in the order of delphinidin > 
malvidin > peonidin > cyanidin > pelargonidin, 
and suggested that the growth inhibitory activ-
ity of these anthocyanidins might be positively 
correlated with the presence of hydroxyl groups 
on ring B of the anthocyanidin molecule, al- 
though the structure-activity relationship is still 
controversial in different cell types [26].
Cell cycle arrest has also been viewed as anoth-
er one of the major underlying mechanisms for 
the cytocidal effects of most chemotherapeutic 
drugs. The cell cycle is a complex process that 
is precisely regulated by vital molecules known 
as cyclin-dependent kinases (CDKs) and CDK 
inhibitors such as p21 and p27 [25, 31, 45, 
46]. In this regard, previous report has demon-
strated that flavone, luteolin and apigenin 
induce forkhead box O3a (FOXO3a) expression 
by inhibiting phosphoinositide 3-kinase (PI3K) 
and Akt, subsequently elevate the expression 
of FOXO3a target genes including p21 and p27, 
ultimately inhibit breast cancer proliferation 
through Akt/FOXO3a-mediated cell cycle arrest 
and apoptosis [45]. Luteolin has also been 
demonstrated to induce cell cycle arrest in 
other cancer cell lines such as colon, pancre-
atic, lung, liver, among others, although differ-
ent cell cycle arrest induction was observed in 
different types of cancer cell lines, suggesting 
its wide range of preventive and therapeutic 
options against various types of cancer [2]. In 
addition, casticin has been reported to sup-
press the phosphorylation of the FOXO3a pro-
tein, the expression of forkhead box M1 
(FOXM1) as well as its downstream genes such 
as CDK1, cell division cycle 25B (cdc25B) and 
cyclin B, and increase the expression of p27, 
ultimately induce G2/M arrest in hepatocellular 
carcinoma cell lines [47]. Induction of cell cycle 
arrest was also observed in hematologic can-
cer cells treated with flavonoids. For instance, 
wogonin, a flavonoid derived from Scutellaria 
baicalensis Georgi, arrested cell cycle at G0/G1 
phase along with the upregulation of p21 and 
downregulation of CDK4 as well as cyclin D1 in 
K562 and K562r (an imatinib-resistant cell 
line) [46]. The binding ability between GATA-
binding factor 1 (GATA-1), a zinc finger transcrip-
tion factor known to induce the differentiation 
of megakaryocytes and erythrocytes, and the 
promoter of p21 in both cells was also enhanced 
after treatment with wogonin for 48 h, suggest-
ing that wogonin induced G0/G1 cell cycle by 
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regulating GATA-1 associated cell cycle check-
points in both cells [46]. Similarly, we also 
reported that Vitex, an extract from the ripe 
fruit of Vitex agnus-castus, induced a dose- and 
time-dependent decrease in cell viability asso-
ciated with induction of apoptosis and G2/M 
cell cycle arrest in HL-60 cells [23]. In addition, 
necrosis is also involved in the antitumor activ-
ity of some flavonoids. Necrosis has been char-
acterized as passive, accidental cell death 
resulting from environmental perturbations 
with uncontrolled release of inflammatory cel-
lular contents [48]. The loss of structural integ-
rity of the plasma membrane is a hallmark of 
necrosis and represents the common final end-
point at which a cell can no longer maintain its 
discrete identity from the environment [48]. 
Despite that apoptosis seems to be clearly 
advantageous for the organism, necrosis induc-
tion still plays critical role in proliferation inhibi-
tion of cancer cells, especially apoptosis-resis-
tant cells [48-50]. Haghiac and colleagues 
have demonstrated that a major dietary flavo-
noid quercetin can inhibit oral cancer cell prolif-
eration through induction of necrosis followed 
by apoptosis, and through S phase cell cycle 
arrest associated with the inhibition of the 
expression of thymidylate synthase, a key S- 
phase enzyme [50]. Furthermore, delphinidin 
has been reported to induce necrosis in hepa-
tocellular carcinoma cells in the presence of 
3-methyladenine, an autophagy inhibitor [49]. 
These results indicate the intricate interplay 
between apoptosis, necrosis as well as autoph-
agy, and suggest that the different death routes 
may overlap, and several characteristics may 
be displayed at the same time. 
Autophagy is a highly conserved catabolic pro-
cess induced under various conditions of cel-
lular stress, and known to positively regulate 
cellular processes for survival or death [25, 31, 
48, 51]. Induction of autophagy by various anti-
cancer drugs has been suggested to be a 
potential therapeutic strategy for cancer [25, 
31, 48, 51]. Zhang and colleagues demonstrat-
ed that aqueous Allspice extract, which con-
tains many different flavonoids, was able to 
activate autophagy signaling in breast cancer 
cells and induce cell death associated with the 
suppression of Akt/mammalian target of ra- 
pamycin (mTOR) signaling in vitro and in vivo 
[52]. Kaempferol has also been demonstrated 
to induce autophagy through adenosine mono-
phosphate activated protein kinase (AMPK) 
and Akt signaling molecules, and cause G2/M 
arrest via downregulation of CDK1/cyclin B in 
SK-HEP-1 human hepatic cancer cells [53]. 
Moreover, induction of autophagy was involved 
in the chemopreventive/chemotherapeutic po- 
tential of genistein, a soy isoflavone, in multiple 
tumor types such as breast cancer, lung cancer 
and hepatoma [51, 54]. The molecular details 
of the contribution of apoptosis, necrosis, cell 
cycle arrest as well as autophagy were summa-
rized in Table 1.
Anti-angiogenic and anti-metastatic properties 
of flavonoids
Angiogenesis is the process which forms new 
blood vessels and occurs in many physiological 
and pathological processes such as reproduce 
in adults, wound healing, tumor development 
and some inflammatory diseases [1, 55, 56]. It 
is a process that is tightly controlled by a wide 
range of angiogenic inducers such as VEGF and 
adhesion molecules as well as various endoge-
nous angiogenesis inhibitors including angio-
statin and thrombospondin. It can also be stim-
ulated by many inflammatory factors, which 
contribute to the pathology of inflammation 
and cancer, indicating angiogenesis, inflamma-
tion and cancer are closely related [1, 55, 56]. 
Uncontrolled angiogenesis is considered as a 
key step in cancer growth, invasion and metas-
tasis, a great deal of attention has thus been 
paid to develop potent inhibitors of angiogene-
sis. In fact, a number of anti-angiogenesis 
drugs have been approved by FDA and are 
being used in cancer treatment [57]. Despite 
this, researchers never stop exploring novel 
candidates of angiogenesis inhibitors due to 
side effects of these drugs [57]. It has been 
demonstrated that wogonin inhibits LPS-
induced tumor angiogenesis via suppressing 
PI3K/Akt/NF-κB signaling in breast cancer cell 
lines in vitro and in vivo [56]. Orientin (luteolin 
8-C-β-D-glucopyranoside), a glycosyl dietary fla-
vonoid, also inhibited invasion by suppressing 
matrix metalloproteinase 9 (MMP-9) and inter-
leukin-8 (IL-8) expression via the intervention 
of protein kinase C alpha (PKCα)/extracellular 
signal regulated kinase (ERK)/nuclear translo-
cations of activator protein-1 (AP-1)/signal tr- 
ansducer and activator of transcription 3 (ST- 
AT3)-mediated signaling pathways in 12-O-te- 
tradecanoylphorbol-13-acetate (TPA)-treated 
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Table 1. The molecular details of the contribution of apoptosis, necrosis, cell cycle arrest as well as autophagy to cancer preventive activities of 
flavonoids
Flavonoids Mechanism of action (Cytotoxicity profiling) Ref.
Casticin Activation of caspase-9, -8, -3; p38 MAPK activation associated with histone H3 phosphorylation (Apoptosis induction, G2/M arrest) [24]
Cytochrome C release, activation of caspase-9, -3 and PARP, activation of JNK; Decrease of mitochondria membrane potential associated 
with dysregulation of Bax/Bcl-2 pathway (Apoptosis induction, G2/M arrest)
[36]
Activation of caspase-9, -3 and PARP, upregulation of Bax and p27; Inhibition of Bcl-2, cyclin D1/CDK4, Akt (Apoptosis induction; G0/G1 
arrest)
[37]
Upregulation of p53, Bax, caspase-3 and p21; Inhibition of polymerization of tubulin, cyclin B1 and CDK1 (Apoptosis induction, G2/M  
arrest)
[38]
Induction of death receptor 5 and Bax, activation of caspase-3 and PARP; Downregulation of Bcl-xL, Bcl-2, survivin, cFLIP, XIAP, pro-form Bid 
(Apoptosis induction)
[39]
Activation of FOXO3a along with downregulation of FOXM1, CDK1, cdc25B, cyclin B1 and upregulation of p27 (G2/M arrest) [47]
Vitexin Activation of intrinsic apoptotic pathway associated with decrease of Bcl-2/Bax ratio, mitochondria membrane potential, cytochrome c 
release and activation of caspase-3; Inhibition of PI3K/Akt/mTOR (Apoptosis induction)
[40]
Quercetin Activation of intrinsic apoptotic pathway associated with upregulation of Bax, Bad, Bid, caspase-9, -3, downregulation of Bcl-2; Bcl-xL, and 
cytochrome c release (Apoptosis induction)
[41]
Activation of caspase-3; Inhibition of thymidylate synthase (Necrosis and apoptosis induction, S phase arrest) [50]
Kaempferol Upregulation of p53 and cleaved-PARP; Inhibition of ERα, Bcl-2, survivin (Apoptosis induction; G2/M arrest) [43]
Upregulation of phosphorylated AMPK, Atg-5, Atg-7, Atg-12, Beclin 1 and LC3-II; Downregulation of CDK1/cyclin B, phosphorylation of Akt 
and mTOR (G2/M arrest, autophagy induction)
[53]
Flavone; apigenin; luteolin Activation of FOXO3a along with upregulation of p27, p21, and downregulation of cyclin B; cyclin D1, induction of p53, cleaved-PARP, cyto-
chrome C; Inhibition of PI3K/Akt pathway (G1, S, and/or G2/M arrest)
[45]
Wogonin Upregulation of GATA-1 and p21; Downregulation of CDK4, cyclin D1, MEK and ERK (G0/G1 arrest) [46]
Delphinidin; Cyanidin-3-rutinoside Induction of cellular vacuolization and LC3-II (Apoptosis, autophagy and necrosis) [49]
Abbreviations: AMPK, adenosine monophosphate activated protein kinase; CDK4, cyclin-dependent kinase 4; cFLIP, cellular FLICE-like inhibitory protein; ERα, estrogen receptor alpha; ERK, extracellular signal 
regulated kinase; FOXM1, forkhead box M1; FOXO3a, forkhead box O3a; GATA-1, GATA-binding factor 1; JNK, Jun-N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein 
kinase kinase; mTOR, mammalian target of rapamycin; PARP, poly ADP-ribose polymerase; PI3K, phosphoinositide 3-kinase; XIAP, X-linked inhibitor of apoptosis protein.
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MCF-7 breast cancer cells [58]. Genistein has 
been found to inhibit angiogenesis through 
manipulating the expression of VEGF, MMPs, 
epidermal growth factor receptor (EGFR) as 
well as NF-κB, PI3-K/Akt, ERK1/2 signaling 
pathways, ultimately causes strong anti-angio-
genic effects [55]. Kaempferol also inhibits 
angiogenic ability by targeting VEGF receptor-2 
and downregulating the PI3K/Akt, mitogen-acti-
vated protein kinase kinase (MEK) and ERK 
pathways in VEGF-stimulated human umbilical 
vein endothelial cells (HUVECs) [59]. In addi-
tion, quercetin has been demonstrated to pos-
sess antimetastatic effects in gastric cancer 
cells via the interruption of urokinase plasmino-
gen activator (uPA)/uPA receptor (uPAR) func-
tion by modulating NF-κB, PKC-δ, ERK1/2, and 
AMPK [60]. More recently, Yao et al. demon-
strated that luteolin significantly inhibited the 
proliferation, migration and invasion of A375 
human melanoma cells, and induced a dose-
dependent apoptosis along with the inhibition 
of the phosphorylation of Akt and PI3K [61]. 
They further demonstrated that luteolin re- 
duced the expressions of MMP-2 and MMP-9 
and increased the expression of tissue inhibitor 
of metalloproteinase (TIMP)-1 and TIMP-2, and 
that luteolin significantly inhibited the tumor 
growth of A375 cells in a xenograft mouse 
model, suggesting that luteolin exhibited its 
antitumor activities by suppressing the expres-
sions of MMP-2 and MMP-9 through the manip-
ulation of PI3K/Akt pathway [61]. The molecu-
lar details of the anti-angiogenic and anti-meta-
static properties of flavonoids were summa-
rized in Table 2.
Immunomodulatory effects of flavonoids
It has been known that flavonoids such as quer-
cetin, fisetin, luteolin and kaempferol have spe-
cific immunomodulatory effects that are might 
be linked to their anti-allergic activities and 
beneficial effects against autoimmune diseas-
es [8, 16-18]. Previous studies on the effects of 
quercetin on the immune system showed its 
inhibitory effects on cytotoxic lymphocyte func-
tion, and clarified that quercetin can affect the 
balance of Th1/Th2 in a murine model of asth-
ma [17]. Fisetin also significantly inhibited Th1 
and Th2 cytokine production, cell cycle and the 
ratio of T CD4+/CD8+ cells in vitro through the 
suppression of NF-κB and nuclear factor of acti-
vated T cells (NFAT) signaling pathway [62]. 
Furthermore, kaempferol has been recently 
reported to enhance the function of CD4+ 
CD25+Foxp3+ regulatory T (Treg) cells by inhibit-
ing FOXP3 phosphorylation [63]. In fact, Treg 
cells have received considerable attention due 
to their immunosuppressive properties in vitro 
and in vivo [64, 65]. These previous findings 
thus support the immunosuppressive effects 
of flavonoids. On the other hand, immunosup-
pression has been widely recognized in cancer 
patients due to immune tolerance induced by 
malignant tumor cells and/or undesirable side-
effects of many types of chemotherapeutic 
drugs [66, 67]. Accumulating evidence has 
shown an increased number and function of 
Treg cells in patients with solid tumors and 
hematologic malignancies, suggesting its criti-
cal role in limiting antitumor immune response 
and promoting immunological ignorance of 
cancer cells [64, 65, 67].
Of note, based on the fact that cancer cells and 
activated Th cells use glycolysis to supply their 
energy needs, and that the PI3K/Akt/mTOR 
pathway plays a crucial role in both cells, a 
recent review article focusing on the effects of 
flavonoids on the immune system and their 
impact on the mTOR pathway demonstrated 
that flavonoids can suppress mTOR activity and 
are consequently able to induce the Treg cell 
subset [17]. Akt/PI3K/mTOR axis is known as 
one of the most important signaling pathway 
linked to the proliferation of various cancer 
cells, and has been considered to be a thera-
peutic target for cancer [1, 16, 17, 25, 31, 33, 
55]. These previous findings thus provide evi-
dence for the pleiotropic effects of flavonoids, 
and suggest that much attention should be 
paid to both the immunosuppressive effects of 
flavonoids and their anticancer efficacy, espe-
cially when combined them with the conven-
tional anticancer drugs.
Effects of flavonoids on drug transporters and 
metabolic enzymes
Since drug action usually requires uptake of the 
drug, it was considered that intracellular drug 
concentrations might determine the efficacy of 
respective drug. Cancer cells usually express a 
high protein level of ATP binding cassette (ABC) 
transporters that can attenuate the efficacy of 
treatment by actively pumping drugs out of the 
cells, leading to the multidrug resistance phe-
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Table 2. The molecular details of anti-angiogenic and anti-metastatic properties of flavonoids
Flavonoids Mechanism of action (Cytotoxicity profiling) Ref.
Wogonin Inhibition of PI3K/Akt/NF-κB pathway and TLR4 pathway, inhibition of VEGF secretion from cancer cells, inhibition of tube formation of HUVECs induced by LPS-
treated MCF-7 cells and vascularization in mice (Angiogenesis suppression without apoptosis induction)
[56]
Orientin Downregulation of MMP-9 and IL-8 via inhibition of PKCα/ERK/AP-1/STAT3 signaling pathway (Inhibition of migration and invasion) [58]
Kaempferol Inhibition of VEGF/VEGFR-2 and its downstream signaling cascades PI3K/Akt; MEK; ERK (Inhibition of migration, invasion, and tube formation) [59]
Quercetin Inhibition of NF-κB, PKC-δ, ERK1/2 along with AMPK activation, and downregulation of uPA/uPAR, MMP-9 and -2 (Inhibition of migration and invasion) [60]
Luteolin Upregulation of TIMP-1 and TIMP-2; Inhibition of PI3K/Akt pathway along with downregulation of MMP-9 and -2 (Apoptosis induction; inhibition of migration and 
invasion)
[61]
Abbreviations: AMPK, adenosine monophosphate activated protein kinase alpha; AP-1, nuclear translocations of activator protein-1; ERK, extracellular signal regulated kinase; HUVECs, human umbilical vein 
endothelial cells; IL-8, interleukin-8; LPS, lipopolysaccharide; MEK, mitogen-activated protein kinase kinase; MMP-9, matrix metalloproteinase-9; NF-κB, nuclear factor kappa B; PKCα, protein kinase C alpha; 
PKC-δ, protein kinase C delta; PI3K, phosphoinositide 3-kinase; STAT3, signal transducer and activator of transcription 3; TIMP-1, tissue inhibitor of metalloproteinase 1;TLR4, Toll-like receptor 4; uPA, uroki-
nase plasminogen activator; uPAR, uPA receptor; VEGF, vascular endothelial growth factor; VEGFR-2, VEGF receptor 2.
Table 3. The molecular details of the differentiation-inducing activity of flavonoids
Flavonoids Mechanism of action (Cytotoxicity profiling) Ref.
Wogonin Upregulation of GATA-1, glycophorin A, CD71, enhancement of the binding between GATA and FOG-1 (Erythroid differentiation 
induction)
[46]
EGCG Upregulation of Bax/Bcl-2 ratio, caspase-8, -3, p-53, PTEN, p21; Inhibition of PML-RARα and HDAC1, downregulation of P-gp 
and MRP1 (Induction of differentiation and apoptosis)
[85]
Kaempferol, genistein, 3’3-diindolylmethane Activation of ROS-p38-p53 signaling pathway and ER stress, upregulation of p21 and Bax; Downregulation of Bcl-2, Cyclin E, 
cyclin B (Apoptosis and differentiation induction)
[86]
Isoliquiritigenin Upregulation of GFAP and β III tubulin; Downregulation of Notch1 and Hes1 (Growth inhibition; differentiation induction) [87]
Genistein Upregulation of E-cadherin, α-SMA, Claudin-1, activation of PI3K/Akt and MEK/ERK pathway; Inhibition of cell population with 
CD44+/CD24-/ESA+, downregulation of fibronectin, slug, snail (Mammosphere formation inhibition, differentiation induction of 
stem/progenitor cells)
[88]
Oroxylin A Upregulation of PKM1/PKM2 ratio and ALB, activation of HNF-4α/HNF-1α, enhancement of binding between PKM1 and HNF-
4α; Downregulation of cyclin A, cyclin B1, AFP, PTB (Proliferation inhibition associated with G2/M arrest, differentiation induc-
tion, tumor growth inhibition of HepG2 xenograft model and PDTX model)
[89]
Abbreviations: AFP, α-fetoprotein; ALB, serum albumin; α-SMA, α-smooth muscle actin; ER stress, endoplasmic reticulum stress; ERK, extracellular signal regulated kinase; GATA-1, GATA-binding factor 1; 
GFAP, glial fibrillary acidic protein; HDAC1, histone deacetylase 1; HNF-1α, hepatocyte nuclear factor 1 alpha; HNF-4α, hepatocyte nuclear factor 4 alpha; MEK, mitogen-activated protein kinase kinase; 
MRP1, multidrug resistance-associated protein 1; PKM1, pyruvate kinase M 1; PKM2, pyruvate kinase M 2; P-gp, P-glycoprotein; PI3K, phosphoinositide 3-kinase; PML-RARα, promyelocytic leukemia protein-
retinoic acid receptor-α; PTB, polypyrimidine tract-binding protein; PTEN, phosphatase and tensin homolog deleted on chromosome 10; ROS, reactive oxygen species.
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notype [6, 68]. It has been established that 
multidrug resistance-associated protein 1 
(MRP1)/MRP2, P-glycoprotein (P-gp), multidrug 
resistance 1 (MDR1) and breast cancer resis-
tance protein (BCRP), which belong to the ABC 
transporter superfamily, play a prominent role 
in the chemoresistance to various anticancer 
drugs [6, 25, 32, 68-72]. Fortunately, flavonoids 
have been demonstrated to serve as modula-
tors of drug transporters and metabolic en- 
zymes, consequently exhibit their cancer che-
mopreventive activity [68-73]. Recently, novel 
flavone derivatives have been demonstrated to 
serve as selective and dual inhibitors of the 
transporters P-gp and BCRP [72]. Nobiletin, a 
major flavonoid compound from oranges (Citrus 
sinensis) peel, has been shown to inhibit MRP1, 
resulting in the accumulation of intracellular 
adriamycin (ADR) in A549 human non-small-
cell lung cancer (NSCLC) cells, ultimately en- 
hance chemosensitivity to ADR [70]. Flavonoids 
including genistein, quercetin, wogonin were 
found to downregulate MRP1 in resistant hu- 
man tumor cell lines, such as pancreatic ade-
nocarcinoma cells (Panc-1) and chronic myelog-
enous leukemia (CML) cells (K562/A02), sug-
gesting their MDR reversal potential [68]. 
Previous reports further demonstrated that fla-
vonoids might inhibit MRP1 by binding to cer-
tain regions of the transporter (substrate-bind-
ing site, nucleotide-binding domains) or deplet-
ing intracellular glutathione [68, 69]. Structure-
activity relationships seem to be linked with the 
inhibition activity against MRP1, suggesting 
that the degrees of hydroxylation and methoxyl-
ation, as well as 2,3-double bonds, play impor-
tant roles in MRP1 inhibition [68]. Regarding 
P-gp, Mohana et al. recently reported that flavo-
noids such as quercetin, rutin, epicatechin 3 
gallate significantly decreased the expression 
of Wnt and glycogen synthase kinase 3beta 
(GSK-3β) in multidrug resistant KBCHR8-5 cells 
and subsequently downregulated P-gp overex-
pression in the cells [74]. Similarly, quercetin 
has been demonstrated to reverse MDR to con-
ventional anticancer drugs including doxorubi-
cin and paclitaxel in breast cancer cells through 
downregulating P-gp expression and eliminat-
ing cancer stem cells mediated by Y-box bind-
ing protein 1 nuclear translocation [75]. In- 
triguingly, opposite effects of flavonoids on the 
expression of P-gp was also observed in quer-
cetin and other flavonoids [68, 76], indicating 
much more complex P-gp-flavonoid interac- 
tions. 
It is well known that cytochrome 450 (CYP450) 
system, one of the most important phase I 
drug-metabolizing enzymes, is involved in the 
oxidative biotransformation of numerous xeno-
biotics and endogenous compounds [68, 73, 
77]. Previous report has clarified that P-gp and 
CYP3A4, a major P450 in humans, share com-
mon regulation pathways and substrates, and 
act synergistically in the intestine to limit the 
bioavailability of their substrates [68]. A great 
deal of attention has been recently paid to 
herb-drug interactions since its high risk medi-
ated by the herbal medicines and dietary sup-
plements containing abundant flavonoids had 
become more and more frequent in our daily 
life [68, 73]. Li and colleagues recently demon-
strated that among 44 different structures of 
flavonoids, several compounds exhibited the 
selective inhibition toward CYP3A4 [73]. They 
further verified drug-drug interaction between 
some flavonoids and clinical drug diazepam in 
human liver microsomes, providing useful mod-
els for early predicting the inhibitory effects of 
different structures of flavonoids toward CYP- 
3A4 [73]. Surprisingly, the oral bioavailability of 
other P-gp/CYP3A4 substrates (tamoxifen, cy- 
closporine) was reduced when coadministered 
with biochanin A, quercetin, known as P-gp/
CYP3A4 inhibitors in rats [68, 78]. These unex-
pected decrease in cyclosporine bioavailability 
might be attributed, at least in part, to CYP3A4 
activation by quercetin serum metabolites [78], 
although more preclinical and clinical investiga-
tion of these interactions are needed to verify. 
These findings thus suggest that systematic 
clinical monitoring and evaluation of intracellu-
lar concentrations of conventional anticancer 
drugs are needed for cancer patients when 
coadministered with herbal medicines contain-
ing flavonoid components. 
Differentiation-inducing activity of flavonoids in 
cancer cells
The aim of differentiation therapy is to induce 
the differentiation of malignant cells, conse-
quently cause them to cease proliferation, ulti-
mately control their tumorigenic and malignant 
potential [79, 80]. Differentiation therapy aris-
es from the fact that leukemic cells have lost 
their ability to differentiate and eventually 
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become malignant [80]. Use of all-trans retino-
ic acid (ATRA) and/or arsenic trioxide in the 
treatment of APL has acquired a therapeutic 
niche, represented as one of most successful 
model of differentiation therapy [6, 81-84]. 
Differentiation therapy possesses the obvious 
characteristics of relatively low toxicity com-
pared with conventional chemotherapy [79, 
80]. Therefore, there is an urgent need to devel-
op novel agents with potent differentiation-
inducing activity and less toxicity for differentia-
tion therapy due to poor cellular differentiation 
of cancer cells and their acquired resistance to 
differentiation agents. 
A previous review [10] highlighting the thera-
peutic potential of natural and synthetic flavo-
noids as anticancer agents in leukemia treat-
ment with respect to the structure-activity rela-
tionships and their molecular mechanisms 
demonstrated that flavones apigenin and luteo-
lin induced HL-60 cells differentiation into gran-
ulocytes, whereas flavonol quercetin induced 
their differentiation into monocytes rather than 
granulocytes. Interestingly, flavonols galangin 
and kaempferol and the flavanone naringenin 
did not induce the differentiation of HL-60 cells 
[10]. These findings concluded that the flavone 
structure might be crucial for the induction of 
differentiation of HL-60 cells into granulocytes 
[10]. More recently, Moradzadeh et al. demon-
strated that green tea polyphenol epigallocate-
chin gallate (EGCG) enhanced differentiation of 
APL cells including HL-60 and NB4 towards 
granulocytic pattern in a similar manner to that 
observed for ATRA [85]. They further demon-
strated that EGCG suppressed the expression 
of clinical marker PML-RARα in NB4 cells and 
reduced the expression of histone deacetylase 
1 (HDAC1) in both HL-60 and NB4 cells [85]. In 
addition, wogonin has been demonstrated to 
induce differentiation of K562, imatinib-resis-
tant K562, and primary patient-derived CML 
cells, along with the upregulation of transcrip-
tion factor GATA-1 and the enhancement of the 
binding between GATA-1 and transcriptional 
coactivator FOG-1 [46]. Flavonoids have also 
recently been demonstrated to induce differen-
tiation in cancer cells derived from various 
types of solid tumors such as breast cancer, 
liver cancer, malignant melanoma glioma [86-
89]. Especially, the differentiation-inducing ac- 
tivity of genistein [88] and isoliquiritigenin [87], 
a member of the flavonoids isolated from lico-
rice (Glycyrrhizae radix), have been reported in 
breast cancer stem/progenitor cells through 
the interaction with ER+ cancer cells by a para-
crine mechanism, and the downregulation of 
the Notch1 signaling pathway, respectively. 
These findings thus provide evidence support-
ing the potential application of flavonoids in the 
treatment of patients with different types of 
cancer. The molecule details of the differentia-
tion-inducing activity were summarized in Table 
3.
Bioavailability of flavonoids
Low bioavailability of flavonoids has been a 
concern as it can limit or even hinder their 
health effects [6, 12, 90]. Flavonoids are pres-
ent in food products mostly in the form of glyco-
sides that are generally hydrolyzed, conse-
quently converted to their respective aglycones 
by intestinal or colon microflora prior to absorp-
tion in the gastrointestinal tract, followed by 
biotransformation to various metabolites which 
enter bloodstream [1, 9, 90, 91]. Previous phar-
macokinetic data indicate that the absorption 
of anthocyanins into the bloodstream of 
rodents and humans is minimal, suggesting 
that they may have little efficacy in tissues 
other than the gastrointestinal tract and skin, 
where they can be absorbed locally [6, 9, 90]. 
Therefore, a number of formulation strategies 
including liposomes, nanoparticles, nanoemul-
sions and mucoadhesive buccal films have 
been developed in recent years in order to max-
imize the bioavailability of flavonoids [1, 90, 92, 
93]. More recently, Deepika and colleagues 
developed a novel therapeutic polymeric com-
plex of rutin (a hydrophobic polyphenolic flavo-
noid phytochemical) and fucoidan (a well-
known sulfated polysaccharide of brown sea-
weed), which aimed to overcoming the limita-
tions of bioavailability of rutin, and showed that 
the rutin-fucoidan complex induced G0/G1 and 
S phase cell cycle arrest, and has the ability to 
induce apoptosis via reactive oxygen species 
generation and mitochondrial potential loss in 
cervical cancer cell, but was biocompatible on 
normal cells [94]. Of note, Chen et al. [95] have 
recently expressed concerns about the poten-
tial toxic effect of some polyphenol including 
apigenin against non-transformed cells when 
used at high concentrations, markedly higher 
than that assumed with diet, suggesting higher 
concentrations of flavonoids could be toxic and 
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therefore more toxicological studies should be 
warranted.
Anticancer activity of combination treatment 
of flavonoids and conventional chemothera-
peutic drugs
Combination treatments, which aims to improve 
overall clinical efficacy, are widely accepted as 
safe and effective approach in cancer therapy 
[6, 96-99]. Due to multidrug resistance and 
tumor recurrence, the development of new 
strategies aimed at improving chemotherapy 
sensitivity and minimizing the adverse side 
effects is still urgently needed. In this regard, 
flavonoids have been considered to be one of 
most promising candidates by virtue of its 
diverse biological properties such as antican-
cer activity [1, 2, 68]. We have previously pro-
vided evidence for the potential combination of 
arsenite and natural product including delphini-
din, one of anthocyanin compounds, against 
human APL cells NB4 and HL-60, in which del-
phinidin sensitized leukemia cells to arsenite 
by strengthening intrinsic/extrinsic pathway-
mediated apoptosis induction, modulating the 
amount of intracellular glutathione and NF-κB 
binding activity [6, 26, 30]. We further demon-
strated that the combination treatment strong-
ly preferred to selectively enhance the cytotox-
icity of arsenite against cancer cells rather than 
human peripheral blood mononuclear cells [26, 
30]. In agreement with our findings, a compre-
hensive review paper recently summarized the 
detailed chemomodulating effects of flavo-
noids in human leukemia cells, and further 
demonstrated that the secondary metabolites 
of flavonoids can also sensitize malignant cells 
to conventional chemotherapeutic drugs and 
could be considered as potential adjunctive 
agents in cancer treatment [3]. Despite a wide 
clinical application of ATRA and its successful 
clinical efficacy in the treatment of APL patient, 
continuous effects have been made to explore 
novel promising candidate aiming to improve 
the effectiveness of ATRA and overcome clini-
cal problems such as resistance. In this regard, 
He and colleagues recently demonstrated that 
dihydromyricetin (DMY), one of flavonoid bioac-
tive compound extracted from Ampelopsis 
grossedentata, exhibited a strong synergy with 
ATRA to promote NB4 cells differentiation 
[100]. They further clarified that DMY sensi-
tized the NB4 cells to ATRA-induced cell growth 
inhibition, CD11b expression, nitrobluetetrazo-
lium (NBT) reduction and myeloid regulator 
expression, all of which seemed to be depen-
dent on the activation of p38-STAT1 signaling 
pathway, providing new opportunities for the 
combination of DMY and ATRA as a promising 
approach for future differentiation therapy 
[100]. 
The beneficial effects of combination treat-
ment are also observed in various types of solid 
tumor cancer cells. Quercetin has been demon-
strated to sensitize human glioblastoma U87 
and U251 cells to temozolomide, an oral alkyl-
ating chemotherapeutic agent, in vitro via inhi-
bition of heat-shock protein 27 [101]. In fact, 
flavonoids including quercetin have been clari-
fied to be able to enter the brain to influence 
brain function by modulating the activity of 
gamma-aminobutyric acid A (GABAA)-receptor 
and monoamine oxidase A/B [102, 103]. 
Similarly, the anticancer potential of combina-
tion of isoflavone biochanin A and temozolo-
mide against glioblastoma U87 and T98G cells 
was reported to be linked to enhanced expres-
sion of p-p53, and inhibition of cell viability, 
expression of cell survival proteins EGFR, 
p-ERK, p-Akt, c-myc and membrane-type-MM- 
P1 [104]. The combination treatment also 
induced G1 arrest, and a shift in the metabolic 
phenotype from glycolytic to oxidative phos-
phorylation in cancer cells [104]. Casticin has 
been demonstrated to potentiate TNF-related 
apoptosis-inducing ligand-induced apoptosis in 
colon cancer cells through downregulation of 
survival proteins such as Bcl-2, Bcl-xL, survivin, 
X-linked inhibitor of apoptosis protein (XIAP) 
and cellular FLICE-like inhibitory protein (cFLIP) 
and upregulation of death receptor 5 [39]. 
Palko-Łabuz et al. recently demonstrated that 
combined use of statins, inhibitors of the key 
enzyme of mevalonate pathway 3-hydroxy-
3-methyl-glutaryl-coenzyme A (HMG-CoA) re- 
ductase, and flavonoids such as baicalein str- 
engthened cell growth inhibition and apoptosis 
induction as compared to the application of 
statins alone to a human colorectal adenocarci-
noma cell line LoVo [71]. They further demon-
strated that in doxorubicin-resistant cell line 
LoVo/Dx, a stronger decrease of resistance to 
doxorubicin was observed in the presence of 
statins in combination with flavones in compari-
son with the effect observed in the presence of 
statins alone [71]. EGCG was recently suggest-
ed to serve as a novel chemo-sensitizer to 
enhance the sensitivity of cancer cells to 5-fluo-
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rouracil (5-FU) by inhibiting glucose-regulated 
protein 78 (GRP78)/NF-κB/miR-155-5p/MDR1 
pathway, and the IC50 values of 5-FU in the 
presence of EGCG were approximately 8-fold 
and 10-fold lower in comparison to the IC50 val-
ues for 5-FU alone in human colon carcinoma 
cell line-HCT-116 and DLD1, respectively [105]. 
A previous clinical study has demonstrated that 
breast cancer patients who are given radiother-
apy plus oral administration of EGCG show sig-
nificantly lower serum levels of VEGF, hepato-
cyte growth factor (HGF), and reduced activa-
tion of MMP9/MMP2, raising the possibility 
that this tea polyphenol has potential to be a 
therapeutic adjuvant against human metastat-
ic breast cancer [106]. Furthermore, luteolin 
has been demonstrated to sensitize human 
breast cancer MDA-MB-231 cells to doxorubi-
cin [107] and paclitaxel [108] by suppressing 
nuclear factor erythroid 2-related factor 2 
(Nrf2) mediated signaling and blocking STAT3, 
respectively. In addition, it has been recently 
demonstrated that a flavonoid compound gla-
bridin can decrease the half maximal inhibitory 
concentration of paclitaxel and doxorubicin in 
breast cancer cells like MDA-MB-231/MDR1 
cells (P-gp overexpressed) and MCF-7/ADR 
cells (P-gp overexpressed and MRP2 expressed) 
[109]. The sensitizing effect of glabridin could 
be explained that it increased the accumula-
tion of doxorubicin in MDA-MB-231/MDR1 cells 
by suppressing the expression of P-gp and com-
petitively inhibiting the P-gp efflux pump, and 
enhanced doxorubicin-mediated apoptosis of 
the cells [109]. Interestingly, Kundur et al. 
recently demonstrated that the combination 
treatment of quercetin and curcumin acted syn-
ergistically to induce anticancer activity against 
triple-negative breast cancer cell (TNBC) lines 
including MDA-MB-231 by enhancing the 
expression of breast cancer type 1 susceptibil-
ity protein, which is mutated in a majority of 
TNBC and cause the loss of function of this 
tumor suppressor gene [110]. 
Moon and colleagues recently reported that 
nobiletin treatment downregulated the expres-
sion of a neuroblastoma-derived MYC (MYCN), 
MRP1, Akt, GSK-3β, β-catenin, and enhanced 
the accumulation of intracellular adriamycin 
(ADR), ultimately enhanced chemosensitivity of 
ADR-resistant a human NSCLC cell line A549/
ADR to ADR [70]. Moreover, it has been recent- 
ly demonstrated that apigenin combined with 
gefitinib, one of EGFR tyrosine kinase inhibi-
tors, inhibits multiple oncogenic drivers such as 
c-Myc, hypoxia-inducible factor 1 alpha (HIF-1α) 
as well as EGFR, and damages the glucose 
uptake and utilization by suppressing glucose 
transporter 1 protein expression on EGFR 
mutant-resistant NSCLC cells, suggesting api-
genin plus gefitinib is a very clinically promising 
combination use [111]. Naringin, a polypheno-
lic flavonoid derive from grapefruit and other 
citrus fruits, can act as a chemosensitizer to 
synergistically strength the cytotoxic effect of 
paclitaxel in human prostate cancer cells 
regardless of androgen dependence by induc-
ing the activation of intrinsic apoptosis path-
way, G1 phase arrest as well as the expression 
of phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) (a major negative regu-
lator of the PI3K/Akt signaling pathway), and 
suppressing cell migration along with the down-
regulation of NF-κB, Snail, Twist and c-Myc 
mRNA expression [112]. These results suggest 
that naringin in combination with paclitaxel 
may be useful in the treatment of prostate can-
cer although more detailed evaluations of the 
mechanism underlying the combination action 
in vivo are obviously needed. The molecule 
details of the enhanced anticancer activity of 
their combination treatment were summarized 
in Table 4.
Conclusions 
Given the importance of flavonoids to cancer 
prevention/therapy as potential adjunctive 
agents and/or chemosensitizer, a long-term 
effort to explore the effects and mechanisms of 
action of flavonoids whatever they are used 
alone or in combination is likely to be contin-
ued. Especially, more clinical trials are obvious-
ly needed to validate the usefulness of flavo-
noid in patients with different characteristics 
such as age, gender, the type and stage of a 
disease, previous treatment history, and other 
medical conditions. Considering the critical role 
of flavonoids in drug-drug interactions and 
novel approach for improving its bioavailability, 
enhanced clinical efficacy of a combinatorial 
treatment regimens of conventional anticancer 
and flavonoids might reasonably be expected. 
Paradoxically, unwanted side effects might 
occur due to enhanced intracellular drug accu-
mulation, suggesting that detailed monitoring 
of clinical efficacy along with the concentra-
tions of drugs and their metabolites should be 
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Table 4. The molecular details of the enhanced anticancer activity of combination treatment of flavonoids and conventional chemotherapeutic 
drugs
Flavonoids Combined drugs Mechanism of action (Combinatorial effect) Ref.
Delphinidin Arsenite Activation of Caspase-8, -9, -3 and Bid; Decrease of GSH and inhibition of NFκB (Enhancement  
of cytotoxicity of arsenite along with apoptosis induction)
[26]
Arsenite Activation of caspase-8, -9, -3 and Bid; Downregulation of mitochondrial membrane potential  
(Enhancement of cytotoxicity)
[30]
Casticin TRAIL Activation of caspase-3/PARP, induction of DR5 mediated by ROS; Downregulation of Bcl-2, Bcl-xL,  
survivin, XIAP, cFLIP (Enhancement of apoptosis induction)
[39]
Baicalein, 6-hydroxyflavone, 7-hydroxyflavone Dox/Sim or Mev Activation of caspase-3 along with DNA fragmentation; Downregulation of proliferating cell nuclear  
antigen (Synergistic effect on growth inhibition along with apoptosis induction)
[71]
Dihydromyricetin ATRA Upregulation of CD11b, PU.1, C/EBPβ, activation of p-38-STAT1 pathway (Synergistic effect on cell  
differentiation)
[100]
Quercetin TMZ Upregulation of Hsp27 phosphorylation, and caspase-3 activity (Enhancement of apoptosis induction) [101]
Biochanin A TMZ Activation of p53; Downregulation of EGFR, phosphorylation of Akt and ERK, c-myc, MT-MMP1, MMP-2,  
and inhibition of complex IV activity (Enhancement of cell viability inhibition associated with G1 phase arrest)
[104]
EGCG 5-FU Activation of caspase-3/PARP, and upregulation of Bad; Inhibition of GRP78/ NF-κB/miR-155-5p/MDR1  
pathway, downregulation of Bcl-2 (Enhancement of cytotoxicity of 5-FU along with apoptosis induction)
[105]
RT Upregulation of Bax; Downregulation of serum levels of VEGF, HGF, MMP-9/MMP-2 in vivo, downregulation  
of Bcl-2, inhibition of c-Met, NF-κB, Akt in vitro (Enhancement of cell growth/invasion inhibition and apopto-
sis induction)
[106]
Luteolin Dox Inhibition of Nrf2 mediated signaling (Enhancement of sensitivity to Dox) [107]
PTX Activation of caspase-8, -3, PARP along with upregulation of Fas; Downregulation of Bcl-xL and inhibition of 
STAT3 (Enhancement of apoptosis induction and tumor growth inhibition)
[108]
Glabridin Dox Inhibition of P-gp expression and function (Increased accumulation of doxorubicin, enhancement of apopto-
sis induction and S phase arrest)
[109]
Quercetin Curcumin Induction of BRCA1 expression, and E-cadherin; Downregulation of MMP-9 (Synergistic effect on cell viability 
and invasion inhibition)
[110]
Naringin PTX/Dox Upregulation of PTEN; Inhibition of NF-κB signaling, and downregulation of survivin, c-myc (Synergistic effect  
on cytotoxicity of drugs associated with apoptosis induction, G1 phase arrest and migration inhibition)
[112]
Abbreviations: 5-FU, 5-fluorouracil; BRCA1, breast cancer type 1 susceptibility protein; C/EBPβ, CCAAT/enhancer-binding protein beta; cFLIP, cellular FLICE-like inhibitory protein; Dox, doxorubicin; DR5, death 
receptor 5; EGFR, epidermal growth factor receptor; ERK, extracellular signal regulated kinase; GSH, glutathione; HGF, hepatocyte growth factor; Hsp27, heat shock protein 27; MDR1, multidrug resistance 1; 
Mev, mevastatin; MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; MT-MMP1, membrane-type matrix metalloproteinase 1; NF-κB, nuclear factor kappa B; Nrf2, nuclear factor erythroid 
2-related factor 2; PARP, poly ADP-ribose polymerase; P-gp, P-glycoprotein; PTEN, phosphatase and tensin homolog deleted on chromosome 10; PTX, paclitaxel, ROS, reactive oxygen species; RT, radiotherapy; 
Sim, simvastatin; STAT1, signal transducer and activator of transcription 1; STAT3, signal transducer and activator of transcription 3; TMZ, temozolomide; VEGF, vascular endothelial growth factor; XIAP, X-linked 
inhibitor of apoptosis protein.
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diligently performed. Overall, further basic and 
clinical researches should be warranted in 
order to provide satisfied chemotherapeutic 
regimens for cancer patients in terms of bio-
availability, efficacy, safety and tolerance.
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